{
    "clinical_study": {
        "@rank": "148211", 
        "arm_group": {
            "arm_group_label": "Arm I", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo laparoscopy for p53 assessment and catheter placement. Patients receive daily intraperitoneal injections of adenovirus p53 (Ad-p53) for 5 days every 3 weeks. Treatment is repeated every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each are treated at each dose level of Ad-p53. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity."
        }, 
        "brief_summary": {
            "textblock": "Phase I trial to study the effectiveness of gene therapy in treating patients with ovarian\n      cancer that has not responded to previous treatment. Inserting the p53 gene into a person's\n      cancer cells may improve the body's ability to fight cancer or make the cancer cells more\n      sensitive to treatment."
        }, 
        "brief_title": "Gene Therapy in Treating Patients With Ovarian Cancer", 
        "condition": "Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the maximum tolerated doses of adenovirus p53 in patients with platinum- and\n      paclitaxel-resistant ovarian epithelial cancer.\n\n      II. Determine the qualitative and quantitative toxic effects of this regimen in these\n      patients.\n\n      III. Document the observed anti-tumor activity of this regimen in these patients.\n\n      IV. Evaluate the biological endpoints (e.g., induction of apoptosis, p53 expression) of this\n      regimen in these patients.\n\n      OUTLINE: This is a dose escalation study.\n\n      Patients undergo laparoscopy for p53 assessment and catheter placement. Patients receive\n      daily intraperitoneal injections of adenovirus p53 (Ad-p53) for 5 days every 3 weeks.\n      Treatment is repeated every 21 days in the absence of disease progression or unacceptable\n      toxicity. Cohorts of 3-6 patients each are treated at each dose level of Ad-p53. The maximum\n      tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose\n      limiting toxicity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed metastatic ovarian epithelial cancer that is platinum- and\n             paclitaxel resistant as defined by: Disease progression while on first-line regimen\n             containing both a platinum drug and paclitaxel OR Tumor progression within 6 months\n             of completion of platinum-based therapy (either as first- or second-line) or\n             paclitaxel-based therapy (either as first- or second-line)\n\n          -  Refractory or recurrent ovarian epithelial cancer as defined by: Lesions of any\n             diameter\n\n          -  Nonmeasurable disease (with CA-125 at least 35)\n\n          -  Ascites and/or pleural effusions allowed\n\n          -  No borderline or low malignant potential tumors\n\n        PATIENT CHARACTERISTICS:\n\n          -  Age: 18 and over\n\n          -  Performance status: Zubrod 0-2\n\n          -  Life expectancy: At least 12 weeks\n\n          -  WBC at least 3,000/mm3\n\n          -  Granulocyte count at least 1,500/mm3\n\n          -  Platelet count at least 100,000/mm3\n\n          -  Bilirubin no greater than 1.5 mg/dL PT/PTT normal\n\n          -  Creatinine no greater than 1.4 mg/dL\n\n          -  No active, unresolved upper respiratory infections\n\n          -  Not HIV positive\n\n          -  At least 5 years since prior malignancy, except nonmelanomatous skin cancer\n\n          -  Willing and able to undergo placement of Tenckhoff catheter in the peritoneal cavity\n             for sampling of ascites or peritoneal fluid\n\n          -  No concurrent serious medical illness\n\n          -  No untreated gastrointestinal obstruction\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n          -  May have failed an unlimited number of prior chemotherapy regimens\n\n          -  At least 30 days since prior chemotherapy\n\n          -  No prior radiotherapy to the pelvis or abdomen\n\n          -  Eligible for laparoscopy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003588", 
            "org_study_id": "NCI-2012-02277", 
            "secondary_id": [
                "MDA-ID-97228", 
                "NCI-T97-0111", 
                "CDR0000066657"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I", 
                "intervention_name": "Ad5CMV-p53 gene", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Arm I", 
                "intervention_name": "laparoscopic surgery", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "stage IV ovarian epithelial cancer", 
            "recurrent ovarian epithelial cancer"
        ], 
        "lastchanged_date": "February 7, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MDA-ID-97228"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "University of Texas - MD Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of Ad-p53 (NSC# 683550) for Patients With Platinum- and Paclitaxel-Resistant Epithelial Ovarian Cancer", 
        "overall_official": {
            "affiliation": "M.D. Anderson Cancer Center", 
            "last_name": "Judith K. Wolf, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2002", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003588"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "September 1998", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2002"
    }, 
    "geocoordinates": {
        "University of Texas - MD Anderson Cancer Center": "29.76 -95.369"
    }
}